16 Aug Moffitt Cancer Center
Moffitt Cell Therapy Facilities (CTFs) experienced team of 80+ professionals offer dynamic cell therapy manufacturing services including product development, optimization, and clinical product manufacturing to assist CTF partners in bringing their assets to clinical trials. Moffitt’s CTF staff and faculty work collaboratively with biopharmaceutical companies to translate cell therapy assets into clinic, and the CTF currently supports 19 INDs which includes biopharmaceutical partners developing cell therapies. Moffitt maintains a patient-centered focus and has extensive experience leading clinical trials in oncology. Recently, Moffitt played a pivotal role in helping bring the first tumor-infiltrating lymphocyte (TIL) product to market in melanoma with the FDA’s approval of Iovance’s Amtagvi. Apart from TIL, Moffitt’s CTF is involved in the development of a wide range of cell therapy modalities, including dendritic cell vaccines, CAR T and gamma delta T cell therapy, with programs in both solid tumors and hematological malignancies.
www.moffitt.org/cell-manufacturing
